*nlm.life
			PubMed Journals: Nat Med

  Source:		PMID: 14981511
  Download:	https://www.nature.com/articles/nm1001.pdf

    		Nat Med. 2004 Mar;10(3):290-3. Epub 2004
     		Feb 22.

			Pegylated interferon-alpha protects type
			1 pneumocytes against SARS coronavirus infection
			in macaques.

			Haagmans BL(1), Kuiken T, Martina BE, Fouchier
			RA, Rimmelzwaan GF, van Amerongen G, van
			Riel D, de Jong T, Itamura S, Chan KH, Tashiro
			M, Osterhaus AD.

			Author Information
			(1) Department of Virology, Erasmus Medical
			Centre, PO Box 1738, 3000 DR, Rotterdam,
			Netherlands.

			The primary cause of severe acute respiratory syndrome
			(SARS) is a newly discovered coronavirus.
			Replication of this SARS coronavirus (SCV)
			occurs mainly in the lower respiratory tract,
			and causes diffuse alveolar damage. Lack
			of understanding of the pathogenesis of
			SARS has prevented the rational development
			of a therapy against this disease. Here we
			show extensive SCV antigen expression in
			type 1 pneumocytes of experimentally infected
			cynomolgus macaques (Macaca fascicularis)
			at 4 d postinfection (d.p.i.), indicating
			that this cell type is the primary target
			for SCV infection early in the disease,
			and explaining the subsequent pulmonary damage.
			We also show that prophylactic treatment
			of SCV-infected macaques with the antiviral
			agent pegylated interferon-alpha (IFN-alpha)
			significantly reduces viral replication
			and excretion, viral antigen expression
			by type 1 pneumocytes and pulmonary damage,
			compared with untreated macaques. Postexposure
			treatment with pegylated IFN-alpha yielded
			intermediate results. We therefore suggest
			that pegylated IFN-alpha protects type 1
			pneumocytes from SCV infection, and should
			be considered a candidate drug for SARS
			therapy.

			DOI: 10.1038/nm1001 PMID: 14981511 [Indexed
			for MEDLINE]

     			                         Tweet       Print